One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]
A known fact is that between 15% to 35% of men who have surgery as their primary treatment after diagnosis of prostate cancer will experience a biochemical recurrence (BCR). The authors of a presentation, Michael B. Williams, MD, et al. presented at the American Urological Association Mid-Atlantic Section - 67th Annual Meeting - October 1 [...]
Concerned that your diabetes could making you more vulnerable to dying from prostate cancer? Yes, diabetes sufferers should be concerned about a potential shorter life span, but not as of a result of prostate cancer (CaP). In the Journal of Clinical Oncology (September 10, 2008), Dr. Matthew Smith and his colleagues reported on the association [...]
Confirming a belief of many of us, new research has found that hormone therapy (endocrine therapy or ADT) is associated with a very large increased risk of developing various major heart problems. This research also tells us that some therapy options have a higher risk profile than others. At Europe's biggest cancer congress, ECCO 15 [...]
Advanced prostate cancer will progress and most of us will face a time when Androgen Deprivation Therapy (ADT) stops working. Most men on ADT take a LHRH agonist, which turns off the production of testosterone (i.e. Lupron) along with a non-steroidal anti-androgen (i.e. Casodex) that prevents the small amount of testosterone that continues to be [...]